NasdaqGS - Nasdaq Real Time Price USD
Regeneron Pharmaceuticals, Inc. (REGN)
623.43 +5.40 (+0.87%)
At close: June 24 at 4:00:01 PM EDT
621.14 -2.13 (-0.34%)
Pre-Market: 4:16:21 AM EDT
Trade REGN on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for REGN
- Previous Close
618.03 - Open
621.35 - Bid 615.35 x 100
- Ask 617.00 x 100
- Day's Range
619.27 - 630.92 - 52 Week Range
514.79 - 821.11 - Volume
773,864 - Avg. Volume
963,506 - Market Cap (intraday)
65.36B - Beta (5Y Monthly) 0.24
- PE Ratio (TTM)
15.22 - EPS (TTM)
40.96 - Earnings Date (est.) Jul 30, 2026
- Forward Dividend & Yield 3.76 (0.60%)
- Ex-Dividend Date May 20, 2026
- 1y Target Est
833.31
Recent News
View More
Performance Overview
Trailing total returns as of 6/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
REGN
19.01%
S&P 500 (^GSPC)
7.49%
1-Year Return
REGN
20.02%
S&P 500 (^GSPC)
20.78%
3-Year Return
REGN
19.39%
S&P 500 (^GSPC)
69.22%
5-Year Return
REGN
15.45%
S&P 500 (^GSPC)
72.47%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/24/2026
Market Cap
65.36B
Enterprise Value
59.31B
Trailing P/E
15.22
Forward P/E
13.89
PEG Ratio (5yr expected)
1.09
Price/Sales (ttm)
4.50
Price/Book (mrq)
2.08
Enterprise Value/Revenue
3.98
Enterprise Value/EBITDA
10.32
Financial Highlights
Profitability and Income Statement
Profit Margin
29.65%
Return on Assets (ttm)
6.13%
Return on Equity (ttm)
14.55%
Revenue (ttm)
14.92B
Net Income Avi to Common (ttm)
4.42B
Diluted EPS (ttm)
40.96
Balance Sheet and Cash Flow
Total Cash (mrq)
8.75B
Total Debt/Equity (mrq)
8.61%
Levered Free Cash Flow (ttm)
3.27B
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreRegeneron's Portfolio Still Supports a Narrow Moat Despite Competitive Threats to Eylea
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
RatingPrice TargetRegeneron's Portfolio Still Supports a Narrow Moat Despite Competitive Threats to Eylea
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
RatingPrice TargetRegeneron Pharmaceuticals Earnings: Top- and Bottom-Line Double-Digit Growth Despite Eylea Declines
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
RatingPrice TargetNear-term challenges limit earnings potential
Regeneron is a biopharmaceutical company focused on treatments for eye diseases, cancer, dermatitis, and rheumatoid arthritis. Founded in 1988, Regeneron has collaborated with Amgen Inc., Procter & Gamble Co., Bayer, Sanofi, and Japan's Sumitomo Chemical Co. The company is a component of the S&P 500, has more than 15,100 employees worldwide, and is based in Tarrytown, New York.
RatingPrice Target